Lipoprotein apheresis, one of the extracorporeal elimination methodologies, combined with higher doses of statins and ezetimibe, is the most effective way to treat homozygotes and statin-refractory heterozygotes of familial hypercholesterolaemia. Promising in particular is the potential for further reduction of LDL-cholesterol-lowering between apheresis.